Bluejay Diagnostics, Inc. announced that the FDA has agreed to consider Bluejay's plan to pursue a De Novo submission for the Symphony IL-6 Test. In written feedback to the January 2022 submission of the FDA pre-submission briefing package, the FDA stated that Bluejay's Symphony IL-6 Test could be considered for the De Novo pathway.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
3.01 USD | -10.68% |
|
-26.23% | -69.16% |
05-31 | Bluejay Diagnostics, Inc. announced a financing transaction | CI |
05-15 | Bluejay Diagnostics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024 | CI |
1st Jan change | Capi. | |
---|---|---|
-69.16% | 1.22M | |
-39.38% | 8.12B | |
+9.28% | 3.62B | |
-1.48% | 2.23B | |
-22.85% | 1.92B | |
-18.07% | 1.66B | |
+10.53% | 931M | |
+17.17% | 729M | |
-9.17% | 694M | |
-33.88% | 472M |
- Stock Market
- Equities
- BJDX Stock
- News Bluejay Diagnostics, Inc.
- Bluejay Reports FDA Agrees to Consider Its Plan to Pursue A De Novo Regulatory Pathway for the Symphony II-6 Test